Keyphrases
Inflammation
100%
Metabolism
100%
Fibrosis
100%
Nuclear Receptor
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Nonalcoholic Steatohepatitis
28%
Cell Death Pathways
28%
Hepatocellular Carcinoma
14%
Cardiovascular Risk
14%
Recent Advances
14%
Transcription Factor
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Treatment Strategy
14%
Novel Therapeutics
14%
Clinical Data
14%
Insulin Resistance
14%
Liver Disease
14%
Metabolic Syndrome
14%
Glucose Homeostasis
14%
Chronic Liver Disease
14%
Liver Inflammation
14%
Multi-organ
14%
Therapeutic Approaches
14%
World Population
14%
Drug Target
14%
Obesity Resistance
14%
End-stage Liver Disease
14%
Peroxisome Proliferator-activated Receptor
14%
Remaining Challenges
14%
Metabolic Comorbidities
14%
Cholesterol Homeostasis
14%
Dysbiosis
14%
Metabolic Derangements
14%
Progressive Form
14%
Pathomechanism
14%
Organ Function
14%
Wide-ranging
14%
Liver Macrophages
14%
Combinational Therapy
14%
Metabolic Disturbances
14%
Multiple Drug Targets
14%
Lipotoxicity
14%
Innate Immune Cell Function
14%
Ligand-controlled
14%
Immunometabolism
14%
Nuclear Receptor Activation
14%
Multiple Mechanisms of Action
14%
Hepatic Factor
14%
Patient-relevant Endpoints
14%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammation
100%
Fibrosis
100%
Nonalcoholic Fatty Liver
100%
Cell Nucleus Receptor
100%
Liver Cell Carcinoma
11%
Liver Disease
11%
Metabolic Syndrome X
11%
Cardiovascular Risk
11%
Insulin Resistance
11%
Chronic Liver Disease
11%
Transcription Factors
11%
End Stage Liver Disease
11%
Dysbiosis
11%
Peroxisome Proliferator Activated Receptor
11%
Lipotoxicity
11%
Comorbidity
11%
Metabolic Disorder
11%
Maturity Onset Diabetes of the Young
11%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Fibrosis
100%
Cell Nucleus Receptor
100%
Cell Death
22%
Hepatocellular Carcinoma
11%
Transcription Factors
11%
Water-Electrolyte Imbalance
11%
Maturity Onset Diabetes of the Young
11%
Immunocompetent Cell
11%
Liver Disease
11%
Metabolic Syndrome
11%
Cardiovascular Risk
11%
Macrophage
11%
Insulin Resistance
11%
Chronic Liver Disease
11%
End Stage Liver Disease
11%
Cell Function
11%
Dysbiosis
11%
Peroxisome Proliferator Activated Receptor
11%
Lipotoxicity
11%
Immunometabolism
11%
Comorbidity
11%
Cholesterol Homeostasis
11%